SG Americas Securities LLC Sells 121,911 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

SG Americas Securities LLC decreased its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 64.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 67,329 shares of the company’s stock after selling 121,911 shares during the period. SG Americas Securities LLC’s holdings in Autolus Therapeutics were worth $244,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Renaissance Technologies LLC grew its holdings in shares of Autolus Therapeutics by 253.5% during the second quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company’s stock valued at $3,985,000 after buying an additional 821,156 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Autolus Therapeutics by 82.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after acquiring an additional 2,487,778 shares during the last quarter. Millennium Management LLC increased its holdings in Autolus Therapeutics by 113.7% in the 2nd quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock valued at $2,829,000 after acquiring an additional 432,503 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Autolus Therapeutics by 2,603.8% in the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company’s stock worth $736,000 after buying an additional 111,131 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in shares of Autolus Therapeutics by 27.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock worth $14,964,000 after buying an additional 925,000 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Performance

Shares of NASDAQ:AUTL opened at $4.52 on Tuesday. The stock has a market capitalization of $1.20 billion, a P/E ratio of -3.77 and a beta of 2.04. Autolus Therapeutics plc has a 52 week low of $2.21 and a 52 week high of $7.45. The firm has a fifty day simple moving average of $3.96 and a two-hundred day simple moving average of $4.10. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, analysts expect that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.